2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: Barcelona

Poster-Relapse Therapy

October 25, 2021

Long-Term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder: Results from the Open-Label Extension Periods of Sakurasky and Sakurastar

Background: Satralizumab reduced relapse risk vs placebo in neuromyelitis optica spectrum disorder (NMOSD) patients and had a favourable...

Read More →

Poster-Non-imaging Biomarkers

October 25, 2021

Concentration of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Cerebrospinal Fluid during Treatment of Patients with Relapsing Multiple Sclerosis in a Phase 2 Study

Background: Evobrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated a low annualized relapse rate (75mg...

Read More →

Poster-Non-imaging Biomarkers

October 25, 2021

The Effect of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis

Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor targeting B cells and myeloid cells. A phase 2 randomized...

Read More →

Poster-Imaging

October 25, 2021

Neural Correlates of Hand Motor Function Revealed By Structural MR Imaging: A Smartphone-Based Remote Assessment Study in People with MS

Background: Regional gray matter pathology is associated with hand motor impairment in people with multiple sclerosis (PwMS). Objectives:...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Background: A global pandemic of COVID-19 has resulted in over 78 million cases as of 23 December 2020. Risks of COVID-19 in people with...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS

Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis

Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...

Read More →

Platform-Neuroimaging

October 25, 2021

A Description of Real-World MRI Acquired in Patients with Multiple Sclerosis: Preliminary Insights from FlywheelMS

Background: Magnetic resonance imaging (MRI) in the context of routine care is an important tool that can inform clinical decisions in...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC